Citi analyst Yigal Nochomovitz lowered the firm’s price target on Arcus Biosciences to $40 from $42 and keeps a Buy rating on the shares. The analyst cites launch timing adjustments for domvanalimab for the target drop.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RCUS: